GLOBEALERT
HEALTHLOWAug 5 · Aug 5, 2026, 4:31 PM

United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged

Seeking Alpha Tech

United Therapeutics expects potential 2027 approvals for ralinepag and Tyvaso IPF while maintaining its 2026 revenue outlook. This provides an update on the company's product pipeline and financial projections.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

More in Health